<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Achieve Life Sciences Inc — News on 6ix</title>
<link>https://6ix.com/company/achieve-life-sciences-inc</link>
<description>Latest news and press releases for Achieve Life Sciences Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 04:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/achieve-life-sciences-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo683541ff78dffbe2df0e118b.webp</url>
<title>Achieve Life Sciences Inc</title>
<link>https://6ix.com/company/achieve-life-sciences-inc</link>
</image>
<item>
<title>Achieve Life Sciences Announces Appointment of Andrew D. Goldberg, MD, as Chief Executive Officer and to the Board of Directors</title>
<link>https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-announces-appointment-of-andrew-d-goldberg-md-as-chief-executive-officer-and-to-the-board-of-directors</link>
<guid isPermaLink="true">https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-announces-appointment-of-andrew-d-goldberg-md-as-chief-executive-officer-and-to-the-board-of-directors</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>Achieve Names Two New Exemplary Healthcare Leaders to its Board of Directors New Leadership and Financing, up to $354 Million ($180 Million Upfront and $174</description>
</item>
<item>
<title>Achieve Life Sciences Announces Up to $354 Million Private Placement</title>
<link>https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-announces-up-to-dollar354-million-private-placement</link>
<guid isPermaLink="true">https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-announces-up-to-dollar354-million-private-placement</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>$180 Million Financing Upfront with Up to an Additional $174 Million from Warrants Exercisable Within 20 Days of FDA Approval Transaction led by Frazier Life</description>
</item>
<item>
<title>Achieve Life Sciences Announces Operational Progress Including Completion of Technology Transfer to Adare Pharma Solutions</title>
<link>https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-announces-operational-progress-including-completion-of-technology-transfer-to-adare-pharma-solutions</link>
<guid isPermaLink="true">https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-announces-operational-progress-including-completion-of-technology-transfer-to-adare-pharma-solutions</guid>
<pubDate>Wed, 15 Apr 2026 04:00:00 GMT</pubDate>
<description>Adare Partnership Provides Supply Chain Redundancy and U.S.-based Manufacturing Capability Company Reiterates Guidance - If Approved, Cytisinicline Commercial</description>
</item>
<item>
<title>Achieve Life Sciences Announces Publication in Nicotine & Tobacco Research Linking Cytisinicline's Receptor Selectivity to Low Nausea Rates and Favorable Tolerability</title>
<link>https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-announces-publication-in-nicotine-and-tobacco-research-linking-cytisiniclines-receptor-selectivity-to-low-nausea-rates-and-favorable-tolerability</link>
<guid isPermaLink="true">https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-announces-publication-in-nicotine-and-tobacco-research-linking-cytisiniclines-receptor-selectivity-to-low-nausea-rates-and-favorable-tolerability</guid>
<pubDate>Thu, 26 Mar 2026 04:00:00 GMT</pubDate>
<description>Preclinical findings show cytisinicline&apos;s minimal 5-HT3 serotonin receptor binding offers insight into observed low nausea rates in smoking and vaping</description>
</item>
<item>
<title>Achieve Life Sciences Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Updates</title>
<link>https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-reports-fourth-quarter-and-full-year-2025-financial-results-and-provides-business-updates</guid>
<pubDate>Tue, 24 Mar 2026 04:00:00 GMT</pubDate>
<description>Achieve also Announces Partnership with U.S.-based Adare Pharma Solutions for Cytisinicline Manufacturing Conference Call Scheduled for 8:30 AM EDT Today,</description>
</item>
<item>
<title>Achieve Life Sciences to Announce Fourth Quarter and Full Year 2025 Financial Results and Host Conference Call and Webcast on March 24, 2026</title>
<link>https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-to-announce-fourth-quarter-and-full-year-2025-financial-results-and-host-conference-call-and-webcast-on-march-24-2026</link>
<guid isPermaLink="true">https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-to-announce-fourth-quarter-and-full-year-2025-financial-results-and-host-conference-call-and-webcast-on-march-24-2026</guid>
<pubDate>Tue, 17 Mar 2026 12:30:00 GMT</pubDate>
<description>SEATTLE and VANCOUVER, British Columbia, March 17, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced it will report its fourth quarter and full year 2025 financial results and provide a corporate update on the cytisinicline development program on Tuesday, March 24, 2026, at 8:30 AM EDT. To access the webca</description>
</item>
<item>
<title>Achieve Life Sciences Presents Data at SRNT Demonstrating Successful Cessation in Smokers with Extensive Prior Treatment Exposure; and on Participant Experience in the ORCA-OL Study</title>
<link>https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-presents-data-at-srnt-demonstrating-successful-cessation-in-smokers-with-extensive-prior-treatment-exposure-and-on-participant-experience-in-the-orca-ol-study-9</link>
<guid isPermaLink="true">https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-presents-data-at-srnt-demonstrating-successful-cessation-in-smokers-with-extensive-prior-treatment-exposure-and-on-participant-experience-in-the-orca-ol-study-9</guid>
<pubDate>Wed, 04 Mar 2026 13:00:00 GMT</pubDate>
<description>A pooled Phase 3 analysis of more than 1,600 people who smoke showed high quit rates; including among those who had previously not succeeded with other smoking cessation medications and regardless of the number of prior quit attempts Late-breaking survey data from year-long ORCA-OL safety study highlight participant experience with extended cytisinicline use SEATTLE and VANCOUVER, British Columbia, March 04, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specia</description>
</item>
<item>
<title>Achieve Life Sciences Announced Granting of New Hire Inducement Awards</title>
<link>https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-announced-granting-210500753</link>
<guid isPermaLink="true">https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-announced-granting-210500753</guid>
<pubDate>Fri, 30 Jan 2026 21:05:00 GMT</pubDate>
<description>SEATTLE and VANCOUVER, British Columbia, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced that effective January 28, 2026, Achieve’s board of directors approved stock option grants to purchase an aggregate of 115,000 shares of its common stock for five new employees under Achieve’s 2024 Equity In</description>
</item>
<item>
<title>Achieve Life Sciences Confirms Promotion of Dr. Mark Rubinstein to Chief Medical Officer</title>
<link>https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-confirms-promotion-134700022</link>
<guid isPermaLink="true">https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-confirms-promotion-134700022</guid>
<pubDate>Mon, 12 Jan 2026 13:47:00 GMT</pubDate>
<description>Experienced medical executive advances to permanent role following successful leadership as Interim CMOSEATTLE and VANCOUVER, British Columbia, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced that it has confirmed the promotion of Mark Rubinstein, M.D., from Interim Chief Me</description>
</item>
<item>
<title>Achieve Life Sciences to Host Meetings During the J.P. Morgan Healthcare Conference Week</title>
<link>https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-host-meetings-210100393</link>
<guid isPermaLink="true">https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-host-meetings-210100393</guid>
<pubDate>Wed, 17 Dec 2025 21:01:00 GMT</pubDate>
<description>Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, announced today that the company will be hosting in-person one-on-one meetings coinciding with the 44th Annual J.P. Morgan Healthcare Conference in San Francisco, January 12-15, 2026.</description>
</item>
<item>
<title>Achieve Life Sciences Reports Third Quarter 2025 Financial Results; Provides Updates on Cytisinicline Program</title>
<link>https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-reports-third-120000186</link>
<guid isPermaLink="true">https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-reports-third-120000186</guid>
<pubDate>Thu, 06 Nov 2025 12:00:00 GMT</pubDate>
<description>One of Only Nine Therapies Chosen for the Inaugural FDA Commissioner’s National Priority Voucher for E-cigarette or Vaping CessationConference Call Scheduled for 8:30 AM EST Today, November 6, 2025 SEATTLE and VANCOUVER, British Columbia, Nov. 06, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, today announced its finan</description>
</item>
<item>
<title>Achieve Life Sciences Meets Key Milestones Advancing Cytisinicline NDA for Smoking Cessation</title>
<link>https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-meets-key-133000865</link>
<guid isPermaLink="true">https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-meets-key-133000865</guid>
<pubDate>Mon, 03 Nov 2025 13:30:00 GMT</pubDate>
<description>120-Day Safety Update Submitted to FDA ORCA-OL Long-Term Safety Trial Successfully ConcludedDSMC Completes Final Review of Cytisinicline, Finds No Drug Safety Concerns SEATTLE and VANCOUVER, British Columbia, Nov. 03, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment for nicotine dependence, today announced several milestones in its ORCA-OL long</description>
</item>
<item>
<title>Achieve Life Sciences to Announce Third Quarter Financial Results and Host Conference Call and Webcast on November 6, 2025</title>
<link>https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-announce-third-123000683</link>
<guid isPermaLink="true">https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-announce-third-123000683</guid>
<pubDate>Wed, 29 Oct 2025 12:30:00 GMT</pubDate>
<description>SEATTLE and VANCOUVER, British Columbia, Oct. 29, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence for smoking cessation, today announced it will report its third quarter 2025 financial results and provide a corporate update on the cytisinicline development program on Thursday, November 6, 2025, at 8:30 AM EST. To access</description>
</item>
<item>
<title>Achieve Life Sciences Appoints Erik Atkisson as Chief Legal Officer</title>
<link>https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-appoints-erik-123000018</link>
<guid isPermaLink="true">https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-appoints-erik-123000018</guid>
<pubDate>Mon, 20 Oct 2025 12:30:00 GMT</pubDate>
<description>New life sciences executive brings more than 25 years of legal expertise spanning clinical and commercial stage biopharmaceutical companiesSEATTLE and VANCOUVER, British Columbia, Oct. 20, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced the appointment of Erik Atkisson as Chief Legal</description>
</item>
<item>
<title>Achieve Life Sciences Receives FDA Commissioner's National Priority Voucher for Cytisinicline for Treatment of Nicotine Dependence for E-cigarette or Vaping Cessation</title>
<link>https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-receives-fda-113000682</link>
<guid isPermaLink="true">https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-receives-fda-113000682</guid>
<pubDate>Fri, 17 Oct 2025 11:30:00 GMT</pubDate>
<description>Potential First-in-Class Treatment for Nicotine E-cigarette or Vaping Cessation Receives Unprecedented Expedited Review Pathway One of Only Nine Therapies Chosen for the FDA’s Inaugural National Priority Voucher Program SEATTLE and VANCOUVER, British Columbia, Oct. 17, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as a treatment of nicotine dependence, tod</description>
</item>
<item>
<title>Achieve Life Sciences Announces Granting of New Hire Inducement Awards</title>
<link>https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-announces-granting-200100414</link>
<guid isPermaLink="true">https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-announces-granting-200100414</guid>
<pubDate>Thu, 02 Oct 2025 20:01:00 GMT</pubDate>
<description>SEATTLE and VANCOUVER, British Columbia, Oct. 02, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced that effective October 1, 2025, Achieve’s board of directors approved stock option grants to purchase an aggregate of 161,000 shares of its common stock for five new employees under Achi</description>
</item>
<item>
<title>Achieve Life Sciences Announces Publication in Thorax of Data Demonstrating Cytisinicline’s Potential Efficacy and Tolerability for Smoking Cessation in Individuals with COPD</title>
<link>https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-announces-publication-123000446</link>
<guid isPermaLink="true">https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-announces-publication-123000446</guid>
<pubDate>Mon, 22 Sep 2025 12:30:00 GMT</pubDate>
<description>New data address critical treatment gap for millions of Americans with COPD who face unique smoking cessation challengesSEATTLE and VANCOUVER, British Columbia, Sept. 22, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline as treatment of nicotine dependence, today announced the publication of new data in Thorax demonstrating that cytisinicline significantly imp</description>
</item>
<item>
<title>Achieve Life Sciences Promotes Craig Donnelly to Chief Operations Officer</title>
<link>https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-promotes-craig-123000679</link>
<guid isPermaLink="true">https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-promotes-craig-123000679</guid>
<pubDate>Thu, 18 Sep 2025 12:30:00 GMT</pubDate>
<description>Donnelly brings more than 25 years of biopharmaceutical expertise in CMC and regulatory operationsSEATTLE and VANCOUVER, British Columbia, Sept. 18, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced the promotion of Craig Donnelly to Chief Operations Officer. Mr. Donnelly has been with</description>
</item>
<item>
<title>Achieve Life Sciences Names Dr. Mark Rubinstein Interim Chief Medical Officer</title>
<link>https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-names-dr-210100124</link>
<guid isPermaLink="true">https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-names-dr-210100124</guid>
<pubDate>Thu, 11 Sep 2025 21:01:00 GMT</pubDate>
<description>SEATTLE and VANCOUVER, British Columbia, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on the global development and commercialization of cytisinicline for treatment of nicotine dependence for smoking cessation, today announced Mark Rubinstein, M.D., will assume the role of Interim Chief Medical Officer (CMO). Dr. Rubinstein will succeed Cindy Jacobs, Ph.D., M.D., who we anticipate will provide advisory servic</description>
</item>
<item>
<title>Achieve Life Sciences Announces FDA Acceptance of Cytisinicline New Drug Application for Treatment of Nicotine Dependence for Smoking Cessation</title>
<link>https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-announces-fda-123000213</link>
<guid isPermaLink="true">https://6ix.com/company/achieve-life-sciences-inc/news/achieve-life-sciences-announces-fda-123000213</guid>
<pubDate>Wed, 03 Sep 2025 12:30:00 GMT</pubDate>
<description>Filing based on pivotal Phase 3 ORCA-2 and ORCA-3 clinical trials demonstrating statistically significant and clinically meaningful smoking cessation FDA acceptance starts the review process and sets timing for potentially the first new FDA-approved pharmacotherapy in two decadesPDUFA targeted date set for June 20, 2026 SEATTLE and VANCOUVER, British Columbia, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage specialty pharmaceutical company focused on t</description>
</item>
</channel>
</rss>